ambossIconambossIcon

Esophageal cancer

Last updated: July 3, 2024

Summarytoggle arrow icon

Esophageal cancer (EC) is the eighth most common type of cancer worldwide and affects men more than women (3:1 ratio). The two main forms are esophageal adenocarcinoma and squamous cell carcinoma. Esophageal adenocarcinomas are among the neoplasms with the fastest increasing incidence in northern and western Europe and North America, while squamous cell carcinoma is the most common form worldwide. Adenocarcinoma, which usually affects the lower third of the esophagus, may be preceded by gastroesophageal reflux disease and Barrett esophagus. Other risk factors include smoking and obesity. Risk factors for squamous cell carcinoma include carcinogen exposure (e.g., in the form of alcohol and tobacco) and a diet high in nitrosamines but low in fruits and vegetables. Locally advanced disease is common at the time of diagnosis because EC is typically asymptomatic early in the disease course. Symptomatic patients may experience weight loss, dyspepsia, progressive dysphagia, cervical adenopathy, hoarseness or persistent cough, and signs of upper gastrointestinal bleeding, such as hematemesis, melena, or anemia. Esophagogastroduodenoscopy (EGD) is used to directly visualize the lesion and obtain a biopsy sample for histopathological confirmation. Staging of the tumor involves CT scan of the chest and abdomen, a PET scan, and often transesophageal endoscopic ultrasound (EUS). Curative surgical resection may be considered for locally invasive cancers, but EC is unresectable in approximately 60% of patients at the time of diagnosis. For patients with unresectable disease, treatment options include chemotherapy, radiation, and palliative stenting. Prognosis is generally poor because of the aggressive nature of EC and oftentimes late diagnosis.

Icon of a lock

Register or log in , in order to read the full article.

Epidemiologytoggle arrow icon

  • Sex: > (3:1) [1]
  • Incidence: an estimated 20,640 new cases of esophageal cancer will be diagnosed in 2022 in the United States [1]
  • Median age of onset: : between 60 and 70 years of age
  • Adenocarcinoma: : most common type of esophageal cancer in the US [2]
  • Squamous cell carcinoma (SCC): most common type of esophageal cancer worldwide [3]

Adenocarcinoma is more common in the US of America.

Epidemiological data refers to the US, unless otherwise specified.

Icon of a lock

Register or log in , in order to read the full article.

Etiologytoggle arrow icon

Adenocarcinoma [4]

The most important risk factors for esophageal adenocarcinoma are gastroesophageal reflux and associated Barrett esophagus.

Squamous cell carcinoma (SCC) [4][5]

The primary risk factors for squamous cell esophageal cancer are alcohol consumption, smoking, and dietary factors (e.g., diet low in fruits and vegetables).

Icon of a lock

Register or log in , in order to read the full article.

Classificationtoggle arrow icon

Siewert classification of adenocarcinoma of the esophagogastric junction [10]

  • Based on the location of the tumor in relation to the Z line
  • Siewert type I and II tumors are managed as esophageal cancer. [11]
Overview of Siewert classification [11]
Type Localization Surgical approaches

Siewert type I

Siewert type II
  • Center of the tumor located from 1 cm above to 2 cm below the Z line
Siewert type III

Icon of a lock

Register or log in , in order to read the full article.

Clinical featurestoggle arrow icon

Early stages [4]

  • Often asymptomatic
  • May manifest with dysphagia or retrosternal discomfort

Advanced stages [4]

Initially, esophageal cancer is often asymptomatic. It typically becomes symptomatic at advanced stages.

Icon of a lock

Register or log in , in order to read the full article.

Diagnosistoggle arrow icon

Esophagogastroduodenoscopy (EGD) with biopsy is the best initial and confirmatory test in patients with suspected esophageal cancer. [12][13]

EGD [14]

Barium swallow [12]

Staging investigations [12]

Consider the following studies in consultation with a multidisciplinary team.

Laboratory studies [4]

Icon of a lock

Register or log in , in order to read the full article.

Stagingtoggle arrow icon

Once the diagnosis is confirmed, EC should be staged to determine management. The American Joint Committee for Cancer (AJCC) TNM classification is currently the standard staging system used in clinical practice.

AJCC staging (8th Edition, 2017) [16]

Icon of a lock

Register or log in , in order to read the full article.

Pathologytoggle arrow icon

Adenocarcinoma [17]

Squamous cell carcinoma [17]

Icon of a lock

Register or log in , in order to read the full article.

Treatmenttoggle arrow icon

General principles

Surgical resection [18]

  • Endoscopic submucosal resection for mucosal lesions [19]
  • Subtotal or total esophagectomy
    • Indications: localized or resectable locally advanced disease
    • Options include: gastric pull-through procedure, colonic interposition

Chemoradiotherapy [18][20]

Other interventional therapy [13]

Icon of a lock

Register or log in , in order to read the full article.

Complicationstoggle arrow icon

Cancer-associated complications

Treatment-associated complications

We list the most important complications. The selection is not exhaustive.

Icon of a lock

Register or log in , in order to read the full article.

Prognosistoggle arrow icon

  • Prognosis is generally poor due to an aggressive course (due to an absent serosa in the esophageal wall) and typically late diagnosis. [12][25]
  • The Surveillance, Epidemiology, and End Results (SEER) database tracks survival rates for patients with EC in the United States.
Estimated survival of patients diagnosed with EC between 2012–2018 [26]
SEER stage 5-year relative survival rate
Localized
  • 47%
Regional
  • 26%
Distant
  • 6%
Combined (any stage)
  • 21%
Icon of a lock

Register or log in , in order to read the full article.

Start your trial, and get 5 days of unlimited access to over 1,100 medical articles and 5,000 USMLE and NBME exam-style questions.
disclaimer Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer